ReviewJournal of neural transmission (Vienna, Austria : 1996)2023
Clinical benefit of MAO-B and COMT inhibition in Parkinson's disease: practical considerations.
Review in Journal of neural transmission (Vienna, Austria : 1996), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 2 syntheses or guidelines pooled it, 66 citations in OpenAlex.
- Levodopa and Plant-Derived Bioactive Compounds in Parkinson's Disease: Mechanisms, Efficacy, and Future Perspectives.CNS neuroscience & therapeutics · 2025Pooled it
- Efficacy of MAO-B and COMT inhibitors on quality of life in patients with Parkinson's disease: a Bayesian network meta-analysis.Frontiers in neurologyPooled it
- Advanced Parkinson's disease treatment patterns in Italy: results from a multicenter observational study.Annals of medicine · 2026Observational
- The safety and tolerability of opicapone in elderly Parkinson's disease patients: a real-world, multicenter, retrospective study.Journal of neural transmission (Vienna, Austria : 1996) · 2026Article
- Carotid body dysfunction contributes to respiratory instability in Rett syndrome.Current biology : CB · 2026Article
- German Delphi consensus: COMT inhibitors in the management of wearing-off fluctuations in Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2026Article
- Rational Design of Multifunctional Tacrine Derivatives as Candidates for the Treatment of Alzheimer and Parkinson Diseases.ChemMedChem · 2026Article
- Review
- The Use of Statins in Parkinson's and Alzheimer's Disease: A 2021-2025 State-of-the-Art Review of Clinical and Preclinical Evidence.Pharmacology research & perspectives · 2026Review
- Parkinson's disease: pathogenesis and therapeutic strategies.Molecular biomedicine · 2026Review
- Motor and non-motor fluctuations in Parkinson's disease: the knowns and unknowns of current therapeutic approaches.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Molecular mechanisms of exercise-induced neuroprotection against Parkinson's disease.Sports medicine and health science · 2026Review
- Effects of MAO-B and COMT Inhibitors on Sleep Disturbances in Patients With Parkinson's Disease: A Network Meta-Analysis.Journal of movement disorders · 2026Article
- Neuroprotective role ofFrontiers in nutrition · 2026Article
- Opicapone in Parkinson's patients with motor fluctuations: clinical assessments and patient-reported outcomes from the OPTI-ON study.Clinical parkinsonism & related disorders · 2026Article
- Neuroprotective and Antioxidant Activity of Newly Synthesized N-Pyrrolyl Hydrazide-Hydrazones in Experimental Models of Neurotoxicity In Vitro and In Vivo.International journal of molecular sciences · 2025Article
- Microwave Imaging for Parkinson's Disease Detection: A Phantom-Based Feasibility Study Using Temperature-Controlled Dielectric Variations.Sensors (Basel, Switzerland) · 2025Article
- The Effect of Dopaminergic Therapies in Parkinson's Disease on Non-Motor Symptoms.International journal of molecular sciences · 2025Review
- Sialic Acid in Neurodegenerative and Psychiatric Disorders: From Molecular Regulation to Targeted Nanocarrier-Based Therapy.Pharmaceutics · 2025Review
- Neuroprotective Attributes of Gut-derived Urolithins in Parkinson's Disease.Molecular neurobiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inhibitors of monoamine oxidase B (MAO-B) and catechol-O-methyltransferase (COMT) are major strategies to reduce levodopa degradation and thus to increase and prolong its effect in striatal dopaminergic neurotransmission in Parkinson's disease patients. While selegiline/rasagiline and tolcapone/entacapone have been available on the market for more than one decade, safinamide and opicapone have been approved in 2015 and 2016, respectively. Meanwhile, comprehensive data from several post-authorization studies have described the use and specific characteristics of the individual substances in clinical practice under real-life conditions. Here, we summarize current knowledge on both medication classes, with a focus on the added clinical value in Parkinson's disease. Furthermore, we outline practical considerations in the treatment of motor fluctuations and provide an outlook on ongoing studies with MAO-B and COMT inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.